El actual tratamiento tributario del Goodwill y el Badwill produce desigualdad tributaria. En el ... more El actual tratamiento tributario del Goodwill y el Badwill produce desigualdad tributaria. En el caso del Goodwill, esta se explica por la imposibilidad de que el contribuyente reconozca pérdidas efectivas surgidas en un proceso de fusión, sino hasta que la organización que las registra se disuelva o lleve a cabo el término de su giro empresarial. En el caso del Badwill, esta surge de la tributación de utilidades que eventualmente ya tributaron en sus orígenes. Estas situaciones podrían incentivar al contribuyente a buscar alternativas para evitar una potencial doble tributación interna o a reconocer, justificadamente y en el corto plazo, las pérdidas generadas en un determinado proceso de fusión de sociedades. Una alternativa para contrarrestar estos efectos es, por medio de una modificación legal, reconocer el genuino derecho a utilizar las pérdidas y buscar una metodología que permita distinguir utilidades que ya tributaron en sus organizaciones de origen.
The Values in Action Inventory of Strengths (VIA-IS) operationalizes 24 character strengths that ... more The Values in Action Inventory of Strengths (VIA-IS) operationalizes 24 character strengths that compose the six virtues proposed in Peterson and Seligman's classification theory. Though the utility of the VIA-IS has been demonstrated in the general population, its applicability to the study of psychosocial adaptation in rehabilitation for individuals with disabilities has been controversial. The present study was to develop a measure of rehabilitation clients' positive traits, the Adapted Inventory of Virtues and Strengths (AIVS) designed to complement the applicability issues of the VIA-IS. Step-by-step AIVS development procedures are presented, and the AIVS factor structure identified via factor analysis is interpreted from a psychosocial adaptation perspective and compared to the VIA-IS factor structure. AIVS subscales include Courage, Integrity, Practical Wisdom, Committed Action, and Emotional Transcendence. Construct validity was assessed by correlating AIVS factors w...
Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement... more Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study. In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAF mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted bl...
Operator productivity targets have led to closer co-operation with catalyst suppliers in producin... more Operator productivity targets have led to closer co-operation with catalyst suppliers in producing transportation fuels and petrochemicals. As well as the formulation of more effective catalysts, a wider array of support services are expected
Esta innovacion obtuvo el Premio Nacional 1998 a la Innovacion Educativa. Anexo C-Innov.2 memoria... more Esta innovacion obtuvo el Premio Nacional 1998 a la Innovacion Educativa. Anexo C-Innov.2 memoria descriptiva y documentacion
We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granuloc... more We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma in a phase II clinical trial. The response of individual lesions, however, was not reported. Since talimogene laherparepvec is thought to mediate anti-tumor activity through both direct tumor cytolysis and induction of systemic tumor-specific immunity, we sought to determine the independent response rate in virus-injected and non-injected lesions. Fifty patients with stage IIIC or IV melanoma were treated with talimogene laherparepvec in a multi-institutional single-arm open-label phase II clinical trial. In this study patients were treated until a complete response was achieved, all accessible tumors disappeared, clinically significant disease progression, or unacceptable toxicity. This report is a post hoc analysis of the systemic effects of talimogene la...
Metastatic melanoma is a very common disease with an increasing incidence worldwide and is notori... more Metastatic melanoma is a very common disease with an increasing incidence worldwide and is notoriously difficult to treat. The long-established treatments including dacarbazine and interleukin-2 have shown limited response rates and are associated with significant toxicities. More recently, treatments have been developed that decrease inhibition of T-cell action against melanomas. Among these, ipilimumab was recently approved for use in metastatic melanoma and has shown improved overall survival (OS) and progression-free survival rates (PFS). Another such treatment currently in development is the monoclonal antibody, anti-PD-1. This blocks PD-1 inhibition of T-cells and has shown promising response rates in early clinical trials. Another treatment approach is to use targeted therapies in patients with mutations in BRAF or CKIT signaling pathways and it is vital that the mutational status of these genes be determined in patients with metastatic melanoma to best determine effective th...
The incidence of multiple pregnancies has increased over the last decade and hence the hospital s... more The incidence of multiple pregnancies has increased over the last decade and hence the hospital stay and perinatal morbidity and mortality. to know the perinatal mortality rate of multiple pregnancies treated in a regional hospital. Retrospective study conducted from the hospital records of deaths that occurred from January 2002 to December 2007 at the Hospital Regional de Especialidades No. 23 IMSS, Monterrey, Nuevo Leon, Mexico. during the study period (six years) were 122,822 births and 95 were multiple pregnancies (0.77/1000 births): 81 (85%) of triplets, 11 (11%) of quadruplets, two of quintillizos and one sextillizos with a total of 303 newborns. 26% (25/95) of multiple pregnancies had one or more deaths. The perinatal mortality rate was 165/1000 births (50/303) compared with that of pregnancies with one fetus in the same period 14.5/1000 births (p<0.0001). 20.9% (17/81) of triplet pregnancies and 54.5% (6/11) of the four had one or more deaths (p<0.02), with a perinatal...
Survivin is a microtubule-associated protein believed to be involved in preserving cell viability... more Survivin is a microtubule-associated protein believed to be involved in preserving cell viability and regulating tumor cell mitosis, and it is overexpressed in many primary tumor types, including melanoma. YM155 is a first-in-class survivin suppressant. The purpose of this Phase 2 study was to evaluate the 6-month progression-free survival (PFS) rate in patients with unresectable Stage III or IV melanoma receiving a combination of YM155 plus docetaxel. The study had two parts: Part 1 established the dose of docetaxel that was tolerable in combination with YM155, and Part 2 evaluated the tolerable docetaxel dose (75 mg/m(2) ) in combination with YM155 (5 mg/m(2) per day continuous infusion over 168 h every 3 weeks). The primary endpoint was 6-month PFS rate. Secondary endpoints were objective response rate (ORR), 1-year overall survival (OS) rate, time from first response to progression, clinical benefit rate (CBR), and safety. Sixty-four patients with metastatic melanoma were treate...
In the USA, the incidence of cutaneous melanoma is increasing rapidly. It has been shown to be re... more In the USA, the incidence of cutaneous melanoma is increasing rapidly. It has been shown to be responsive to immune-stimulating drugs. Allovectin-7® allows the immune system to recognize metastatic melanoma lesions as foreign by incorporating a MHC class I complex into the tumor through direct injection. Once transfected, tumor biopsies have shown an increased presence of cytotoxic T lymphocytes in the tumor beds themselves. Phase I and II trials have shown local and systemic response to these tumors, with an excellent safety profile. Currently, a Phase III trial has completed enrollment and is set to determine the safety and efficacy of treatment in comparison with standard chemotherapy.
El actual tratamiento tributario del Goodwill y el Badwill produce desigualdad tributaria. En el ... more El actual tratamiento tributario del Goodwill y el Badwill produce desigualdad tributaria. En el caso del Goodwill, esta se explica por la imposibilidad de que el contribuyente reconozca pérdidas efectivas surgidas en un proceso de fusión, sino hasta que la organización que las registra se disuelva o lleve a cabo el término de su giro empresarial. En el caso del Badwill, esta surge de la tributación de utilidades que eventualmente ya tributaron en sus orígenes. Estas situaciones podrían incentivar al contribuyente a buscar alternativas para evitar una potencial doble tributación interna o a reconocer, justificadamente y en el corto plazo, las pérdidas generadas en un determinado proceso de fusión de sociedades. Una alternativa para contrarrestar estos efectos es, por medio de una modificación legal, reconocer el genuino derecho a utilizar las pérdidas y buscar una metodología que permita distinguir utilidades que ya tributaron en sus organizaciones de origen.
The Values in Action Inventory of Strengths (VIA-IS) operationalizes 24 character strengths that ... more The Values in Action Inventory of Strengths (VIA-IS) operationalizes 24 character strengths that compose the six virtues proposed in Peterson and Seligman's classification theory. Though the utility of the VIA-IS has been demonstrated in the general population, its applicability to the study of psychosocial adaptation in rehabilitation for individuals with disabilities has been controversial. The present study was to develop a measure of rehabilitation clients' positive traits, the Adapted Inventory of Virtues and Strengths (AIVS) designed to complement the applicability issues of the VIA-IS. Step-by-step AIVS development procedures are presented, and the AIVS factor structure identified via factor analysis is interpreted from a psychosocial adaptation perspective and compared to the VIA-IS factor structure. AIVS subscales include Courage, Integrity, Practical Wisdom, Committed Action, and Emotional Transcendence. Construct validity was assessed by correlating AIVS factors w...
Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement... more Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study. In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAF mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted bl...
Operator productivity targets have led to closer co-operation with catalyst suppliers in producin... more Operator productivity targets have led to closer co-operation with catalyst suppliers in producing transportation fuels and petrochemicals. As well as the formulation of more effective catalysts, a wider array of support services are expected
Esta innovacion obtuvo el Premio Nacional 1998 a la Innovacion Educativa. Anexo C-Innov.2 memoria... more Esta innovacion obtuvo el Premio Nacional 1998 a la Innovacion Educativa. Anexo C-Innov.2 memoria descriptiva y documentacion
We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granuloc... more We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma in a phase II clinical trial. The response of individual lesions, however, was not reported. Since talimogene laherparepvec is thought to mediate anti-tumor activity through both direct tumor cytolysis and induction of systemic tumor-specific immunity, we sought to determine the independent response rate in virus-injected and non-injected lesions. Fifty patients with stage IIIC or IV melanoma were treated with talimogene laherparepvec in a multi-institutional single-arm open-label phase II clinical trial. In this study patients were treated until a complete response was achieved, all accessible tumors disappeared, clinically significant disease progression, or unacceptable toxicity. This report is a post hoc analysis of the systemic effects of talimogene la...
Metastatic melanoma is a very common disease with an increasing incidence worldwide and is notori... more Metastatic melanoma is a very common disease with an increasing incidence worldwide and is notoriously difficult to treat. The long-established treatments including dacarbazine and interleukin-2 have shown limited response rates and are associated with significant toxicities. More recently, treatments have been developed that decrease inhibition of T-cell action against melanomas. Among these, ipilimumab was recently approved for use in metastatic melanoma and has shown improved overall survival (OS) and progression-free survival rates (PFS). Another such treatment currently in development is the monoclonal antibody, anti-PD-1. This blocks PD-1 inhibition of T-cells and has shown promising response rates in early clinical trials. Another treatment approach is to use targeted therapies in patients with mutations in BRAF or CKIT signaling pathways and it is vital that the mutational status of these genes be determined in patients with metastatic melanoma to best determine effective th...
The incidence of multiple pregnancies has increased over the last decade and hence the hospital s... more The incidence of multiple pregnancies has increased over the last decade and hence the hospital stay and perinatal morbidity and mortality. to know the perinatal mortality rate of multiple pregnancies treated in a regional hospital. Retrospective study conducted from the hospital records of deaths that occurred from January 2002 to December 2007 at the Hospital Regional de Especialidades No. 23 IMSS, Monterrey, Nuevo Leon, Mexico. during the study period (six years) were 122,822 births and 95 were multiple pregnancies (0.77/1000 births): 81 (85%) of triplets, 11 (11%) of quadruplets, two of quintillizos and one sextillizos with a total of 303 newborns. 26% (25/95) of multiple pregnancies had one or more deaths. The perinatal mortality rate was 165/1000 births (50/303) compared with that of pregnancies with one fetus in the same period 14.5/1000 births (p<0.0001). 20.9% (17/81) of triplet pregnancies and 54.5% (6/11) of the four had one or more deaths (p<0.02), with a perinatal...
Survivin is a microtubule-associated protein believed to be involved in preserving cell viability... more Survivin is a microtubule-associated protein believed to be involved in preserving cell viability and regulating tumor cell mitosis, and it is overexpressed in many primary tumor types, including melanoma. YM155 is a first-in-class survivin suppressant. The purpose of this Phase 2 study was to evaluate the 6-month progression-free survival (PFS) rate in patients with unresectable Stage III or IV melanoma receiving a combination of YM155 plus docetaxel. The study had two parts: Part 1 established the dose of docetaxel that was tolerable in combination with YM155, and Part 2 evaluated the tolerable docetaxel dose (75 mg/m(2) ) in combination with YM155 (5 mg/m(2) per day continuous infusion over 168 h every 3 weeks). The primary endpoint was 6-month PFS rate. Secondary endpoints were objective response rate (ORR), 1-year overall survival (OS) rate, time from first response to progression, clinical benefit rate (CBR), and safety. Sixty-four patients with metastatic melanoma were treate...
In the USA, the incidence of cutaneous melanoma is increasing rapidly. It has been shown to be re... more In the USA, the incidence of cutaneous melanoma is increasing rapidly. It has been shown to be responsive to immune-stimulating drugs. Allovectin-7® allows the immune system to recognize metastatic melanoma lesions as foreign by incorporating a MHC class I complex into the tumor through direct injection. Once transfected, tumor biopsies have shown an increased presence of cytotoxic T lymphocytes in the tumor beds themselves. Phase I and II trials have shown local and systemic response to these tumors, with an excellent safety profile. Currently, a Phase III trial has completed enrollment and is set to determine the safety and efficacy of treatment in comparison with standard chemotherapy.
Uploads
Papers by René Ricardo Borrego González